- Home
- EYPT vs LZB Comparison
EYPT vs LZB Comparison
Compare EYPT & LZB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | LZB |
|---|---|---|
| Founded | 1987 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Home Furnishings |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EYPT | LZB |
|---|---|---|
| Price | $12.86 | $32.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $31.80 | ★ $42.50 |
| AVG Volume (30 Days) | ★ 1.2M | 360.5K |
| Earning Date | 03-04-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $7,539,000.00 | ★ $2,349,433,000.00 |
| Revenue This Year | N/A | $1.89 |
| Revenue Next Year | $1,031.72 | $2.09 |
| P/E Ratio | ★ N/A | $19.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $29.03 |
| 52 Week High | $19.11 | $44.49 |
Technical Indicators
Market Signals| Indicator | EYPT | LZB |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 40.18 |
| Support Level | $12.05 | $31.99 |
| Resistance Level | $13.32 | $33.90 |
| Average True Range (ATR) | 1.01 | 0.82 |
| MACD | -0.33 | -0.09 |
| Stochastic Oscillator | 3.45 | 34.03 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.